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OBJECTIVES: To evaluate the effect of Carbopol gel formulations containing pilocarpine on the morphology
and morphometry of the vaginal epithelium of castrated rats.
METHODS: Thirty-one female Wistar-Hannover rats were randomly divided into four groups: the control Groups I
(n=7, rats in persistent estrus; positive controls) and II (n=7, castrated rats, negative controls) and the experimental
Groups, III (n=8) and IV (n=9). Persistent estrus (Group I) was achieved with a subcutaneous injection of
testosterone propionate on the second postnatal day. At 90 days postnatal, rats in Groups II, III and IV were
castrated and treated vaginally for 14 days with Carbopol gel (vehicle alone) or Carbopol gel containing 5% and
15% pilocarpine, respectively. Next, all of the animals were euthanized and their vaginas were removed for
histological evaluation. A non-parametric test with a weighted linear regression model was used for data analysis
(po0.05).
RESULTS: The morphological evaluation showed maturation of the vaginal epithelium with keratinization in
Group I, whereas signs of vaginal atrophy were present in the rats of the other groups. Morphometric
examinations showed mean thickness values of the vaginal epithelium of 195.10±12.23 mm, 30.90±1.14 mm,
28.16±2.98 mm and 29.84±2.30 mm in Groups I, II, III and IV, respectively, with statistically significant differences
between Group I and the other three groups (po0.0001) and no differences between Groups II, III and IV
(p=0.0809).
CONCLUSION: Topical gel formulations containing pilocarpine had no effect on atrophy of the vaginal
epithelium in the castrated female rats.
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’ INTRODUCTION
Menopausal symptoms resulting from ovarian failure,
such as hot flashes, bone mass loss, urinary complaints and,
principally, vaginal dryness and dyspareunia caused by
vaginal atrophy, are common symptoms that cause menopau-
sal women to consult their physicians (1). Estrogen is the most
common treatment for vaginal atrophy resulting from hypoes-
trogenism; however, alternative treatments exist. Recently,
CO2 laser therapy has been shown to be a safe and effective
option for the treatment of vulvovaginal atrophy symptoms in
post-menopausal women (2). This treatment is particularly
relevant for women with breast cancer. Other treatments
include lubricants for vaginal dryness and dyspareunia (3).
The use of estrogen is contraindicated for the treatment of
vaginal atrophy in menopausal women with hormone-
dependent cancer; therefore, alternative treatments need to
be identified. Pilocarpine chloride is a non-hormonal
substance that has attracted the interest of investigators. It
is a cholinergic parasympathomimetic agonist with a broad
pharmacological effect and predominant muscarinic activity
(3,4) that induces an increase in glandular secretion,
principally in the salivary and sweat glands (5). Some
investigators have demonstrated an improvement in dry
mouth and dry eye symptoms as well as an improvement in
vaginal dryness in patients with Sjögren’s syndrome who use
pilocarpine (6). Nevertheless, other authors have failed to
confirm that oral pilocarpine produces an improvement in
vaginal dryness humans (7).DOI: 10.6061/clinics/2016(05)09
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BASIC RESEARCH
The oral use of pilocarpine is associated with undesirable
side effects; however, for ethical reasons, studying the
application of pilocarpine directly on the vaginal tissue of
menopausal women is not possible. Therefore, experimental
models need to be identified. From a morphological and
endocrine viewpoint, the animal model that is most similar
to humans is the female rat (8). The castrated female rat is a
biological model with a vaginal epithelium that mimics that
of postmenopausal women and therefore, growing interest
exists in studying the interaction of various substances in this
model. Conversely, the female rat in persistent estrus is a
biological model that is characterized by interruption of the
estrous cycle and persistent keratinization of the vaginal
epithelium due to the effect of constant estrogen production,
thus mimicking polycystic ovary syndrome (9,10). Therefore,
due to the controversies associated with the relatively few
studies that have been conducted and the need for
alternatives to estrogen therapy for women with vaginal
atrophy and hormone-dependent cancer, the present study
was conducted.
’ MATERIALS AND METHODS
Animals
The present study was designed in accordance with the
ethical principles established by the Brazilian College of
Animal Research and approved by the Animal Research
Ethics Committee of the Federal University of Piauí, Brazil
(protocol number 012/14). All efforts were made to minimize
the number of animals used and to prevent pain, stress or
distress in the rats. Thirty-one virgin female Wistar-Hannover
rats weighing approximately 200 grams and obtained from the
animal laboratory of the School of Veterinary Science, Federal
University of Piauí were used in this study. The animals were
randomly divided into four groups: Group I: positive controls
(n=7 rats in permanent estrus), Group II: negative controls
(n=7 castrated rats treated with vehicle only, Carbopol gel),
Group III: 5% experimental group (n=8 castrated rats treated
with Carbopol gel containing 5% pilocarpine) and Group IV:
15% experimental group (n=9 castrated rats treated with
Carbopol gel containing 15% pilocarpine). Permanent estrus
was achieved in the animals in Group I by administering a
subcutaneous injection of 1.25 mg of testosterone propionate
diluted in 0.1 ml of corn oil on the second postnatal day. Estrus
was confirmed in the animals at 90 days postnatal based on the
total elimination of the external third of the vagina (11) and the
presence of keratinization of the vaginal wall epithelium,
which are the principal characteristics of persistent estrus that
are found during histological examinations at necropsy (9).
At 90 days postnatal, the rats in Groups II, III and IV were
castrated following a subcutaneous administration of keta-
mine/midazolam anesthesia. Hypoestrogenism, which is
characterized by the absence of mature cells and a predomi-
nance of basal cells, was confirmed in Papanicolaou-stained
vaginal smears performed 30 days after castration (12).
Subsequently, the animals in Group I were given only water
and food ad libitum, whereas those in Groups II, III and IV also
received 0.1 ml of Carbopol gel (the vehicle), Carbopol
gel containing 5% pilocarpine or Carbopol gel containing
15% pilocarpine vaginally for 14 days, respectively. On the
15th day, all animals were euthanized. The vaginas were
removed through a longitudinal abdominal incision and fixed
in 10% buffered formalin for 12-24 hours. The specimens were
then dehydrated in increasing ethanol concentrations until
reaching absolute ethanol, cleared in xylene, embedded in
liquid paraffin and placed in an oven at a temperature of 59oC
to produce the tissue blocks (13).
Morphological and Morphometric Study
For the morphological and morphometric evaluations, 5-mm
cross sections were obtained and then the slides were stained
with hematoxylin and eosin. An evaluation was conducted
using a 400x light microscope connected to a color digital
video camera (model SCC-131), which captured and trans-
mitted images to a computer equipped with the Imagelabs
software program for image analysis. The morphological
evaluation analyzed maturation, cell stratification and the
presence of keratin. In the morphometric analysis of the
vaginal epithelium, the epithelial thickness was defined as
the mean of four linear measurements in mm, measured in
the thickest areas (12).
Statistical analysis
Aweighted linear regression model was fitted to compare
the mean epithelial thickness of the animals in the four
groups. The weight measurements consisted of the inverse of
the variance of each group compared to the heteroscedasti-
city of the control group (po0.05).
’ RESULTS
The morphological analysis of the vaginal epithelium of
the rats in Group I (persistent estrus) showed a mature
epithelium with a predominance of superficial cells and
keratin, whereas in the vaginal epithelium of the castrated
animals in Groups II (vehicle), III (5% pilocarpine) and IV
(15% pilocarpine) exhibited a predominance of deep cells
(basal and parabasal cells) (Figure 1). The morphometric
evaluation revealed mean thickness values (±standard
deviation) of 195.10±12.23 mm, 30.90±1.14 mm, 28.16±2.98
mm and 29.84±2.30 mm in Groups I, II, III and IV, respectively
(Table 1). The mean thickness of the vaginal epithelium of
rats in Group I (permanent estrus) was significantly greater
than that of animals in Groups II, III or IV (po0.0001), with
no statistically significant differences between groups II, III
and IV (p=0.0809).
’ DISCUSSION
The number of menopausal women is increasing world-
wide. In a study conducted in six countries, approximately
45% of menopausal women reported symptoms occurring as
a result of ovarian failure (14). Vaginal atrophy, the principal
consequence of which is vaginal dryness and dyspareunia, is
the most common symptom, affecting between 10 and 50%
of menopausal women (15,16). In female breast cancer
survivors, the prevalence of vaginal dryness is 61.5%, which
is higher than that found in the general population of
menopausal women (17). Therefore, we have attempted to
identify a non-estrogenic alternative to improve vaginal
atrophy and dryness in these women.
These results showed that the thickness of the vaginal
epithelium was significantly greater in female rats in perma-
nent estrus than in groups of castrated female rats treated
vaginally with Carbopol gel and pilocarpine. In addition, no
statistically significant difference was found between the
castrated rats that were treated with the vehicle (Carbopol)
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alone and those that were treated with the different concen-
trations of pilocarpine.
We are unaware of any other study in which the effect of a
Carbopol gel containing pilocarpine was evaluated in the
vagina of castrated female rats. Studies on the direct effects
of Carbopol gel containing pilocarpine on the urogenital
epithelium of women with vaginal atrophy are not possible
for ethical reasons. However, in some laboratory animals
such as female rats, the anatomical structure and the
histology of the urogenital tract are similar to those of
humans, rendering these models biologically relevant for the
study of factors that are related to female urogenital
disorders (18). Unlike the castrated female rats that were
used as negative controls in this study due to their ability to
mimic menopausal women, female rats in permanent estrus
were used as positive controls because the constant
estrogenic stimulus is a marked characteristic of polycystic
ovary syndrome, and women with this syndrome are
affected by a constant influx of estrogen (19).
The most effective therapy used to reduce the symptoms of
atrophic vaginitis is estrogen therapy, which is most commonly
administered topically, thus avoiding increased exposure to
systemic estrogen (20,21). Oral pilocarpine has been associated
with toxicity (7); therefore, the vaginal route of administration
was selected for the present study. Pilocarpine was incorpo-
rated into a Carbopol 940-based gel because it is an inexpensive
hydrophilic gel that has the additional advantage of remaining
in place for a longer period of time due to its mucoadhesive
properties (22,23). The Carbopol gel contained 5% and 15%
concentrations of pilocarpine, which are doses that have been
used in other studies (6,7,24,25).
Figure 1 - Photomicrographs of histological sections of the vaginal epithelium of rats. Note the thickness of the vaginal epithelium (E)
and keratin in rats in persistent estrus (A) and the thin layer of basal and parabasal cells in the castrated rats of Groups II (vehicle) (B),
III (5% pilocarpine) (C) and IV (15% pilocarpine) (D). Original magnification 100x.
Table 1 - Means and standard deviations of the vaginal epithelium
thickness of female rats in persistent estrus (Group I, positive
control) and the castrated rats in Groups II (negative control),
III and IV (experimental groups) treated with gels with vehicle
and pilocarpine.
Epithelial thickness (lm)
Group n Mean SD
I 7 195.10* 12.23
II 7 30.90 1.14
III 8 28.16 2.98
IV 9 29.84 2.30
Group I exhibited a significantly greater epithelial thickness than Groups II,
III and IV (po0.0001) and no difference was observed between Groups II, III
and IV (p=0.0809).
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Vivino et al. (6) conducted a phase III trial with pilocarpine
in patients with Sjögren’s syndrome in which the main
endpoint was an improvement in oral and ocular dryness
and they also observed a statistically significant decrease in
vaginal dryness. Thus, these results suggested that pilocar-
pine could possibly be used to treat vaginal dryness. The
proposed mechanism of action is thought to occur via
cholinergic stimulation of Bartholin’s glands, thus increasing
mucus production and moisture in the vaginal area (7).
Conversely, Loprinzi et al. (7) conducted a clinical trial and
failed to find any beneficial effect of the oral use of pilocarpine
for reducing vaginal dryness in women with vaginal atrophy.
The results of these investigators are consistent with the
findings of the present study, which showed no detectable
effect of vaginal pilocarpine on atrophy of the vaginal
epithelium of castrated female rats. Further studies are needed
to identify other alternative treatments.
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